ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.492,49
1,22%
S&P 500
5.459,10
1,11%
US Dollar vs BRL
5,6561
0,00%
Bitcoin
67.846,79
-0,10%
Brent Oil
79,745
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) Notícias

REGN Regeneron Pharmaceuticals Inc

1.078,63
14,44 (1,36%)
26 Jul 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Regeneron Pharmaceuticals Inc REGN NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
14,44 1,36% 1.078,63 19:01:24
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
1.067,54 1.073,76 1.091,305 1.078,63 1.064,19
mais cotações »

Notícias Recentes

Data Hora Fonte Título
03/07/202402:00GLOBEDupixent® (dupilumab) Approved in the European Union as the..
02/07/202413:53PRNUSKuehn Law Encourages Investors of Regeneron Pharmaceuticals,..
28/06/202408:00GLOBEOdronextamab Recommended for EU Approval by the CHMP to..
27/06/202417:05GLOBERegeneron to Report Second Quarter 2024 Financial and..
26/06/202418:30GLOBEDupixent® (dupilumab) Positive Phase 3 Data in Children 1 to..
16/06/202407:10GLOBEUpdated Linvoseltamab Data Showcase Continued Deepening of..
11/06/202408:00GLOBEKevzara® (sarilumab) Approved by FDA for the Treatment of..
31/05/202402:05GLOBEDupixent® (dupilumab) Recommended for EU Approval by the..
31/05/202402:00GLOBEUpdate on FDA Priority Review of Dupixent® (dupilumab) for..
29/05/202408:15PRNUSBiohaven Doses First Patient with its Novel Trop-2 Directed..
23/05/202418:03GLOBEPromising Anti-tumor Activity of Novel Costimulatory..
20/05/202415:15GLOBEDupixent® (dupilumab) Late-Breaking Data from NOTUS..
17/05/202414:45GLOBEMore than $9 Million Awarded to High School Scientists and..
13/05/202402:00GLOBEDupixent® (dupilumab) sBLA Accepted for FDA Priority Review..
08/05/202407:00GLOBELatest DB-OTO Results Show Dramatically Improved Hearing to..
06/05/202417:05GLOBERegeneron Announces Investor Conference Presentations
02/05/202407:30GLOBERegeneron Reports First Quarter 2024 Financial and Operating..
29/04/202408:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO..
25/04/202408:00GLOBERegeneron and Mammoth Biosciences Collaborate to Pursue..
24/04/202411:05GLOBERegeneron to Showcase Progress in Advancing Novel..
22/04/202418:54GLOBERegeneron to Highlight Advances in Genetic Medicine Research..
16/04/202408:18IHMARKETNEWSEricsson Soars with 66% Net Profit Growth; Live Nation Under..
11/04/202408:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
07/04/202417:00GLOBELinvoseltamab Pivotal Data Presented at AACR Reinforce High..
01/04/202417:05GLOBERegeneron to Report First Quarter 2024 Financial and..
25/03/202408:00GLOBERegeneron Provides Update on Biologics License Application..
13/03/202400:55PRNUSHigh School Seniors Win $1.8 Million at Regeneron Science..
12/03/202422:30GLOBEHigh School Seniors Win $1.8 Million at Regeneron Science..
11/03/202408:00GLOBEPraluent® (alirocumab) Injection Receives FDA Approval to..
08/03/202409:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet..
23/02/202403:00GLOBEDupixent® (dupilumab) sBLA Accepted for FDA Priority Review..
21/02/202409:00GLOBELinvoseltamab BLA for Treatment of Relapsed/Refractory..
16/02/202402:59GLOBEJapan First in the World to Approve Dupixent® (dupilumab)..
06/02/202418:05GLOBERegeneron Announces Investor Conference Presentations
02/02/202408:30GLOBERegeneron Reports Fourth Quarter and Full Year 2023..
02/02/202408:00GLOBELinvoseltamab Receives EMA Filing Acceptance for Treatment..
30/01/202411:25APSBiotech Shares Soar Premarket On Sale Of R&D Assets
30/01/202409:00GLOBERegeneron Announces Formation of Regeneron Cell Medicines..
25/01/202416:29GLOBEDupixent® (dupilumab) FDA Approved as First and Only..
24/01/202414:05PRNUSTop 40 High School Scientists in Prestigious Regeneron..
24/01/202414:00GLOBETop 40 High School Scientists in Prestigious Regeneron..
16/01/202409:00GLOBEDupixent® (dupilumab) U.S. Label Updated with Data Further..
08/01/202409:30PRNUSMedison Pharma Announces Agreement with Regeneron..
05/01/202418:05GLOBERegeneron to Report Fourth Quarter and Full Year 2023..
18/12/202318:05GLOBERegeneron Announces Presentation at the 42nd Annual J.P...
11/12/202309:30GLOBERegeneron Named on Dow Jones Sustainability World Index for..
10/12/202321:30GLOBELatest Odronextamab Data in Relapsed/Refractory Follicular..
10/12/202314:30GLOBEUpdated Odronextamab Data from Relapsed/Refractory Diffuse..
07/12/202309:00GLOBEUpdated Linvoseltamab Pivotal Data Demonstrated Strong Rates..
07/12/202304:30GLOBERegeneron to Share Progress of Novel Combination Therapies..

Seu Histórico Recente

NASDAQ
REGN
Regeneron Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados